Navigation Links
KAHR Medical Granted U.S. Patent Approval for One of its Lead Products in Development, KAHR-101
Date:2/4/2013

JERUSALEM, Feb. 4, 2013 /PRNewswire/ -- Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: HADSY), a publicly traded portfolio of biotech companies, based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, today announced that its portfolio company, KAHR Medical Ltd. ("KAHR"), was granted a U.S. patent approval (U.S. Patent No. 8329657).  

This patent approval follows other patents already received in the U.S., Europe, Japan and Israel, protecting different combinations of KAHR's 'Signal Converting Proteins (SCPs)', which are bi-functional chimeric proteins with synergistic effects that improve the efficiency of pharmaceutical treatments. The newly issued patent protects one of KAHR's products in development, KAHR-101, which has been shown to be effective in the treatment of various cancers, arthritis and multiple sclerosis in animal models.

Ophir Shahaf , CEO of Hadasit Bio-Holdings, stated, "KAHR Medical develops ground-breaking products and we are constantly working to strengthen the company's intellectual property. The company uses a novel technology by which two therapeutic pathways can be simultaneously stimulated by a single protein drug in a synergistic manner, optimizing the care provided to patients. The completion of a recent fundraising round a few months ago will allow for further development and advancement of KAHR's drugs. We believe that in the coming year our portfolio companies will continue to present considerable clinical and business developments increasing their value as well as ours."

About KAHR Medical Ltd.

KAHR Medical is developing an innovative platform technology that produces a large number of protein-based drugs with two complementary targets. The leading products in KAHR's pipeline are designed to treat several types of cancer and diseases of the immune system. The Signal Converting Proteins (SCPs) can activate or block two biological signals in parallel, as opposed to the conventional drugs available today which address a single aspect of the disease. The original SCP technology was developed at the University of Pennsylvania and at Hadassah by the Head of the Nephrology Department, Dr. Michal Dranitzki - Elhalel. Hadasit Bio-Holdings currently holds about 55% of the company, Sanofi owns approximately 20% of the company and Thomas Eldred , owner of Recipharm (a leading European drug manufacturer), holds approximately 15%.

For more information about KAHR Medical please visit: www.kahr-medical.com

For more information about Hadasit Bio-Holdings please visit: www.hbl.co.il

Investor Contact:
KCSA Strategic Communications
Phil Carlson / Josh Dver
212.896.1233 / 1239
pcarlson@kcsa.com / jdver@kcsa.com

 


'/>"/>
SOURCE Hadasit Bio-Holdings Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lung Cancer Alliance Congratulates 75 Medical Centers For Moving Swiftly And Responsibly On Lung Cancer Screening
2. Medical Device Developers - Network at BIOMEDevice Boston Next Week
3. Winner Medicals Special Committee Appoints Independent Financial Advisor and Retains Legal Counsel
4. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
5. CareFusion to Sell Neurodiagnostic Business to Natus Medical for $58 Million
6. ulrich medical USA™ Releases New Expandable Spinal Implant for US Market
7. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
8. Essential Medical Dismisses Patent Case against Masimo and Cercacor
9. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
10. Aethlon Medical Note: Marc Robins Joins the Aethlon Team
11. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... for their devotion to personalized service, SMP Pharmacy Solutions announces ... the South Florida Business Journal,s 50 Fastest-Growing Companies, and listed ... national specialty pharmacy has found its niche.  To that end, ... honored by SFBJ as the 2017 Power Leader in Health ... his award in October, Bardisa said of the three achievements, ...
(Date:9/22/2017)... Sept. 22, 2017  As the latest Obamacare repeal ... Bill Cassidy (R-LA) and Lindsey Graham ... the medical device industry is in an odd place. ... the 2.3% excise tax on medical device sales passed ... want covered patients, increased visits and hospital customers with ...
(Date:9/18/2017)... PROVIDENCE, R.I. , Sept. 18, 2017 ... in the fields of bioinformatics and immune ... to develop a protective avian influenza A (H7N9) vaccine. ... is distantly related to seasonal influenza and ... approaches, which rely on prior exposure to be ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... As health professionals work to improve ... engagement.” The patient is doing more than filling out a survey; in many cases ... an increasing emphasis in health care and research on the importance of active engagement ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along ... updates for the primary prevention of cardiovascular diseases during the 15th Annual ...
(Date:10/13/2017)... New York, NY (PRWEB) , ... October 13, 2017 , ... ... most influential people in business to advocate for action towards gender equality at their ... 18,000 views from around the globe, and reached a social audience of over 3 ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the Mission ... lost souls in the Philippines. “The Journey: From the Mountains to the Mission Field” ... the Bible. She has taught all ages and currently teaches a class of ladies ...
(Date:10/12/2017)... Wis. (PRWEB) , ... October 12, 2017 , ... ... standard products to meet the demand of today’s consumer and regulatory authorities worldwide. ... of probiotic experts and tested to meet the highest standard. , These ...
Breaking Medicine News(10 mins):